Pacific Biosciences Appoints Michael J. Glynn as Chief Commercial Officer

MENLO PARK, Calif.–(BUSINESS WIRE)–

Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of

Single Molecule Real Time (SMRT^®) sequencing products, today

announced the appointment of Michael J. Glynn as Chief Commercial

Officer.

Michael Glynn has more than 40 years of experience in global commercial

operations. Prior to joining Pacific Biosciences, Mr. Glynn served as

Regional President, Japan – Asia Pacific and Senior Vice President at

Genzyme Corporation. In this role, he was responsible for leading and

managing Genzyme’s businesses in Japan and Asia Pacific from the

company’s regional headquarters in Singapore.

Prior to joining Genzyme in January 2007, Mr. Glynn was with Boston

Scientific for seven years, most recently as President of its

Endovations division in the United States, and prior to that as Vice

President and General Manager, Asia, Middle East, and Turkey. From

1995-2000 he was President and CEO of Codman Group, a developer of

healthcare decision support software and home telemedicine systems

(formerly Caremonitor, Inc.). He also spent seven years with Memtec

Limited as President of Memtec Japan and President of Memtec America.

Before joining Memtec he spent ten years with Baxter International in

Australia and the United States where he held a variety of management

positions in manufacturing, quality assurance, marketing, and strategic

planning. Earlier in his career Mr. Glynn held a variety of

manufacturing and technical management positions with companies in

Australia and England, including Burroughs Wellcome, Estee Lauder, and

Elizabeth Arden. He holds an M.B.A. from Macquarie University in Sydney

and a B.S. from the National University of Ireland.

“Michael has exceptional commercial experience with an emphasis on

customer satisfaction and support for industry-leading companies

operating in global markets,” said Hugh Martin, Chairman and Chief

Executive Officer of Pacific Biosciences. “He has excellent capabilities

to lead the next phase of our commercialization strategy for the PacBio RS,

and his deep experience with clinical products will be

extremely important as next generation sequencing moves closer to

patient care.”

In this new position, Mr. Glynn will oversee the day-to-day management

of Pacific Biosciences’ commercial operations, including all field

sales, support and marketing activities.

“As someone who has lived and worked on four continents I am thrilled to

be joining the exceptional team at Pacific Biosciences as the company

ramps up its commitment to providing commercial operations around the

world,” said Mr. Glynn. “PacBio’s recently introduced, game-changing

technology has already shown the tremendous impact it can have in public

health applications such as pathogen detection. I look forward to

helping the company build a world-class commercial operation that will

create further value for our customers.”

For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.

You can also follow the company on twitter www.twitter.com/pacbio.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires,

processes and interprets data from living systems through the design,

development and commercialization of innovative tools for biological

research. The company has developed a novel approach to studying the

synthesis and regulation of DNA, RNA and proteins. Combining recent

advances in nanofabrication, biochemistry, molecular biology, surface

chemistry and optics, Pacific Biosciences has created a powerful

technology platform called single molecule, real-time, or SMRT^®,

technology. SMRT technology enables real-time analysis of biomolecules

with single molecule resolution, which has the potential to transform

the understanding of biological systems by providing a window into these

systems that has not previously been open for scientific study.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. Such statements include, but are not

limited to, statements regarding the Company’s SMRT technology. These

statements are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those expressed or

implied by such statements, including but not limited to risks discussed

from time to time in documents Pacific Biosciences of California, Inc.

has filed with the Securities and Exchange Commission, including the

risks identified under the section captioned “Risk Factors” in its

recently filed Quarterly Report on Form 10-Q. All forward-looking

statements are based on estimates, projections and assumptions as of the

date hereof. Pacific Biosciences undertakes no obligation to update any

forward-looking statements.

For Pacific BiosciencesNicole Litchfield, 415-793-6468 (Media)
nicole@bioscribe.com
or
Pacific

BiosciencesTrevin Rard, 650-521-8450 (Investors)
ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media